Yen Wen Yu
Vermögen: 4 Mio $ am 30.09.2026
Vermögen: 4 Mio $ am 30.09.2026
Mr. Yen Wen Yu is a Chief Operating Officer at Disc Medicine, Inc. Mr. Yu was previously employed as a Vice President-Finance & Operations by Qpex Biopharma, Inc. and a VP-Strategic Planning & Corporate Development by The Medicines Co. He received his undergraduate degree from Harvard College and an MBA from The Wharton School of the University of Pennsylvania.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DISC MEDICINE, INC. 0.14% | 25.08.2026 | 54’324 ( 0.14% ) | 4 Mio $ | 30.09.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| DISC MEDICINE, INC. | Geschäftsführer | 07.02.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
Qpex Biopharma, Inc.
Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery, development and regulatory services for clinical-stage biopharmaceutical company | Gründer | 01.07.2020 |
| THE MEDICINES COMPANY | Corporate Officer/Principal | 01.07.2018 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
The Medicines Co.
The Medicines Co. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for acute cardiovascular care | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard College
Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Qpex Biopharma, Inc.
Qpex Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery, development and regulatory services for clinical-stage biopharmaceutical company | Health Technology |
Disc Medicine, Inc.
Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen